马来酸桂哌齐特联用依达拉奉治疗急性脑梗死疗效观察及安全性研究

目的观察马来酸桂哌齐特联用依达拉奉治疗急性脑梗死的临床疗效及安全性。方法将118例脑梗死患者随机分为观察组62例和对照组56例。观察组应用马来酸桂哌齐特160mg加入0．9％氯化钠250ml静脉滴注，1次／d；依达拉奉30mg溶于0．9％氯化钠100ml静脉滴注，2次，d，连用2周。对照组予血栓通500mg＋0．9％氯化钠250ml静脉滴注，1次，d，胞磷胆碱500mg＋0．9％氯化钠100ml静脉滴注，1次，d，连用2周。对治疗前及治疗14d后进行神经功能缺损（NIHSS）评分。且治疗前后对两组进行疗效评定。结果观察组与对照组治疗14d后NIHSS评分均明显降低，与治疗前比较，差异均有统计学意义（P〈0．05），并且观察组明显低于对照组（P〈0．05）。两组治疗14d后，观察组显效率51．61％，总有效率93．54％，均优于对照组（25．00％，78．58％），两组比较，差异有统计学意义俨〈0．05）。结论马来酸桂哌齐特联用依达拉奉治疗急性脑梗死，对患者神经功能的恢复及预后疗效显著。

Efficacy and safety analysis of combining cinepazide maleate with edaravone on the treatment of acutecerebral infarction

Objective To observe the clinical efficacy and safety of combining cinepazide maleate with edaravon on the treatment of acute cerebral infarction. Methods 118 patients with cerebral infarction were randomly divided into control group（62 cases） and observation group（56 cases）. Observation group were treated with cinepazide maleate 160 mg using 0.9% sodium chloride 250 ml as the solvent, once a day; and edaravone 30 mg using 0.9% sodium chloride 100 ml as the solvent, twice a day. Control group were treated with Xueshuantong 500 mg using 0.9% sodium chloride 250 ml as the solvent, once a day; and citicoline 500 mg using 0.9% sodium chloride 100 ml as the solvent, once a day. Both groups continuously used by intravenous drip for 14 days. Then assess the national institutes of health stroke scale （NIHSS） before and after 14 days＇ treatment respectively. Furthermore, evaluate the curative effect on both groups. Results The NIHSS of observation group and control group were both dramatic decline after 14 days＇ treatment. The difference was statistically significant comparing with those before treatment （P〈0.05）. What＇s more, observation group was significantly lower than control group （P〈0.05）. After 14 days＇ treatment, the significant efficiency of observation group was 51.6%, the total efficiency was 93.5%, which were better than control group （25%, 78.6%）. There were significant differences between the two groups （P〈0.05）. Conclusion The recovery of neurological function and prognosis curative effect is remarkable in patients with acute cerebral infarction who treated with combining cinepazide and edaravone.